skip to content
Control of Visceral Leishmaniasis by Immunotherapeutic and Prophylactic Strategies. Preview this item
ClosePreview this item
Checking...

Control of Visceral Leishmaniasis by Immunotherapeutic and Prophylactic Strategies.

Author: Jesus G. Valenzuela.; Hira L. Nakhasi.; Nahid Ali.; Alexandre Barbosa Reis.
Publisher: Frontiers Media SA 2015.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Visceral leishmaniasis (VL) or kala-azar is the most dreadful of all forms of leishmaniasis caused by Leishmania donovani in Old World and Leishmania chagasi and/or Leishmania infantum in New World affecting millions of people worldwide. In active VL, macrophages host the replicating amastigotes in phagolysosomal compartments leading to splenomegaly, hepatomegaly, hyperglobulinemia, anemia, weight-loss, incessant  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Jesus G. Valenzuela.; Hira L. Nakhasi.; Nahid Ali.; Alexandre Barbosa Reis.
ISBN: 9782889195527 288919552X
OCLC Number: 945783429
Language Note: English.
Description: 1 electronic resource (144 pages)
Other Titles: Directory of open access books.

Abstract:

Visceral leishmaniasis (VL) or kala-azar is the most dreadful of all forms of leishmaniasis caused by Leishmania donovani in Old World and Leishmania chagasi and/or Leishmania infantum in New World affecting millions of people worldwide. In active VL, macrophages host the replicating amastigotes in phagolysosomal compartments leading to splenomegaly, hepatomegaly, hyperglobulinemia, anemia, weight-loss, incessant fever and ultimately death if not treated. Treatments available against the disease are limited by increased incidence of resistance, serious side-effects, high cost and long course of treatment. Immuno-chemotherapy is an alternative to overcome the limitations of the drugs against VL. Combination of one or more of immunotherapeutic agents like BCG, Alum, IFN-?, antigen-pulsed dendritic cells (DC), etc. with chemotherapeutic drugs have been tested raising hopes for a suitable immuno-chemotherapy against VL and Post Kala-azar Dermal Leishmaniasis (PKDL). Antagonists of IL-10, TGF-ß, IL-13 have been effectively used with pentavalent antimonials in treatment of experimental VL. Some parasitic antigens and liposomal formulations have also been shown to impart superior therapeutic effectiveness to antileishmanial drugs. For socio-economic reasons prophylaxis is always more desirable than therapy. Although no vaccine against any form of leishmaniasis in humans is available, patients successfully treated show considerable protection from reinfection highlighting the possibility of developing prophylactic measures against the disease. Subsequently a lot of interest has been focused recently towards developing vaccines against VL and many potential vaccine candidates like whole cell (attenuated or heat killed), crude fractions, purified subunits, DNAs, recombinant proteins, fusion proteins, and genetically modified live attenuated parasites etc. have been reported. These vaccine candidates are either activators of CD4+Th1 cells and/or CD8+ T cells or neutralizers of immuno-suppression. Cationic liposomal formulations, nanoparticle and virosome delivery systems, etc. have been used to increase potency and durability of various vaccine candidates. Immuno-modulators like TLR agonists have been shown to be promising adjuvants in enhancing efficacy and overcoming the challenge of human administrable vaccine formulations. Recently role of sand fly salivary gland proteins as immune-modulators also has been explored. Various strategies such as heterologous prime boosting, targeted antigen delivery, adjuvant mediated protection, have been undertaken. Likewise, precise role of regulatory T cells (Tregs) in VL disease progression needs to be investigated and exploited to develop both immuno-therapeutic and prophylactic methods. A breakthrough in immunotherapy and prophylactic strategy would help in eradication of the parasites from the pool of natural reservoirs namely VL and PKDL patients, asymptomatic carrier individuals and infected dogs ensuring success of global VL control programs.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/945783429> # Control of Visceral Leishmaniasis by Immunotherapeutic and Prophylactic Strategies.
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
   library:oclcnum "945783429" ;
   rdfs:seeAlso <http://experiment.worldcat.org/entity/work/data/2969391386#CreativeWork/directory_of_open_access_books> ; # Directory of open access books.
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Thing/immunotherapy> ; # Immunotherapy
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Thing/visceral_leishmaniasis> ; # Visceral leishmaniasis
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Thing/immuno_modulator> ; # Immuno modulator
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Thing/vaccine> ; # Vaccine
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Topic/medicine_general> ; # Medicine (General)
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Thing/th1_response> ; # Th1 response
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Topic/public_aspects_of_medicine> ; # Public aspects of medicine
   schema:about <http://experiment.worldcat.org/entity/work/data/2969391386#Topic/immunologic_diseases_allergy> ; # Immunologic diseases. Allergy
   schema:author <http://experiment.worldcat.org/entity/work/data/2969391386#Person/hira_l_nakhasi> ; # Hira L. Nakhasi.
   schema:author <http://experiment.worldcat.org/entity/work/data/2969391386#Person/jesus_g_valenzuela> ; # Jesus G. Valenzuela.
   schema:author <http://experiment.worldcat.org/entity/work/data/2969391386#Person/nahid_ali> ; # Nahid Ali.
   schema:author <http://experiment.worldcat.org/entity/work/data/2969391386#Person/alexandre_barbosa_reis> ; # Alexandre Barbosa Reis.
   schema:bookFormat schema:EBook ;
   schema:datePublished "2015" ;
   schema:description "Visceral leishmaniasis (VL) or kala-azar is the most dreadful of all forms of leishmaniasis caused by Leishmania donovani in Old World and Leishmania chagasi and/or Leishmania infantum in New World affecting millions of people worldwide. In active VL, macrophages host the replicating amastigotes in phagolysosomal compartments leading to splenomegaly, hepatomegaly, hyperglobulinemia, anemia, weight-loss, incessant fever and ultimately death if not treated. Treatments available against the disease are limited by increased incidence of resistance, serious side-effects, high cost and long course of treatment. Immuno-chemotherapy is an alternative to overcome the limitations of the drugs against VL. Combination of one or more of immunotherapeutic agents like BCG, Alum, IFN-?, antigen-pulsed dendritic cells (DC), etc. with chemotherapeutic drugs have been tested raising hopes for a suitable immuno-chemotherapy against VL and Post Kala-azar Dermal Leishmaniasis (PKDL). Antagonists of IL-10, TGF-ß, IL-13 have been effectively used with pentavalent antimonials in treatment of experimental VL. Some parasitic antigens and liposomal formulations have also been shown to impart superior therapeutic effectiveness to antileishmanial drugs. For socio-economic reasons prophylaxis is always more desirable than therapy. Although no vaccine against any form of leishmaniasis in humans is available, patients successfully treated show considerable protection from reinfection highlighting the possibility of developing prophylactic measures against the disease. Subsequently a lot of interest has been focused recently towards developing vaccines against VL and many potential vaccine candidates like whole cell (attenuated or heat killed), crude fractions, purified subunits, DNAs, recombinant proteins, fusion proteins, and genetically modified live attenuated parasites etc. have been reported. These vaccine candidates are either activators of CD4+Th1 cells and/or CD8+ T cells or neutralizers of immuno-suppression. Cationic liposomal formulations, nanoparticle and virosome delivery systems, etc. have been used to increase potency and durability of various vaccine candidates. Immuno-modulators like TLR agonists have been shown to be promising adjuvants in enhancing efficacy and overcoming the challenge of human administrable vaccine formulations. Recently role of sand fly salivary gland proteins as immune-modulators also has been explored. Various strategies such as heterologous prime boosting, targeted antigen delivery, adjuvant mediated protection, have been undertaken. Likewise, precise role of regulatory T cells (Tregs) in VL disease progression needs to be investigated and exploited to develop both immuno-therapeutic and prophylactic methods. A breakthrough in immunotherapy and prophylactic strategy would help in eradication of the parasites from the pool of natural reservoirs namely VL and PKDL patients, asymptomatic carrier individuals and infected dogs ensuring success of global VL control programs."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/2969391386> ;
   schema:inLanguage "en" ;
   schema:name "Control of Visceral Leishmaniasis by Immunotherapeutic and Prophylactic Strategies."@en ;
   schema:productID "945783429" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/945783429#PublicationEvent/frontiers_media_sa2015> ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/2969391386#Agent/frontiers_media_sa> ; # Frontiers Media SA
   schema:url <http://www.doabooks.org/doab?func=fulltext&rid=18161> ;
   schema:url <http://journal.frontiersin.org/researchtopic/1970/control-of-visceral-leishmaniasis-by-immunotherapeutic-and-prophylactic-strategies> ;
   schema:workExample <http://worldcat.org/isbn/9782889195527> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/945783429> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2969391386#Agent/frontiers_media_sa> # Frontiers Media SA
    a bgn:Agent ;
   schema:name "Frontiers Media SA" ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#CreativeWork/directory_of_open_access_books> # Directory of open access books.
    a schema:CreativeWork ;
   schema:name "Directory of open access books." ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#Person/alexandre_barbosa_reis> # Alexandre Barbosa Reis.
    a schema:Person ;
   schema:name "Alexandre Barbosa Reis." ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#Person/jesus_g_valenzuela> # Jesus G. Valenzuela.
    a schema:Person ;
   schema:name "Jesus G. Valenzuela." ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#Thing/visceral_leishmaniasis> # Visceral leishmaniasis
    a schema:Thing ;
   schema:name "Visceral leishmaniasis" ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#Topic/immunologic_diseases_allergy> # Immunologic diseases. Allergy
    a schema:Intangible ;
   schema:name "Immunologic diseases. Allergy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#Topic/medicine_general> # Medicine (General)
    a schema:Intangible ;
   schema:name "Medicine (General)"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2969391386#Topic/public_aspects_of_medicine> # Public aspects of medicine
    a schema:Intangible ;
   schema:name "Public aspects of medicine"@en ;
    .

<http://worldcat.org/isbn/9782889195527>
    a schema:ProductModel ;
   schema:isbn "288919552X" ;
   schema:isbn "9782889195527" ;
    .

<http://www.worldcat.org/title/-/oclc/945783429>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/945783429> ; # Control of Visceral Leishmaniasis by Immunotherapeutic and Prophylactic Strategies.
   schema:dateModified "2017-12-22" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.